Log in to search using one of your social media accounts:

 

Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma

Despite the availability of novel treatments for multiple myeloma, resistance to chemotherapy inevitably develops. We retrospectively reviewed the outcomes of patients with relapsed and/or refractory disease treated with modified hyperCVAD (n = 15) or bortezomib-hyperCAD (n = 18). Effectiveness and safety outcomes were similar in each group, with the entire cohort of patients demonstrating an overall response rate of 42%.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

A higher risk for a variety of cancers is among the major complications of posttransplantation immunosuppression. In this part of a continuing series on cancers posttransplantation, this review focuses on the hematologic cancers after solid organ transplantation. Posttransplantation lymphoproliferative disorders (PTLDs), which comprise the great majority of hematologic cancers, represent a spectrum of conditions that include, but are not limited to, the Hodgkin and non‐Hodgkin lymphomas. The oncogenic Epstein‐Barr virus is a key pathogenic driver in many PTLD cases, through known and unknown mechanisms. The other hemat...
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Tags: COMPREHENSIVE REVIEW Source Type: research
This study focuses on the efficacy of pegfilgrastim in PBSC mobilization compared to filgrastim exclusively after novel agent-based induction in a homogeneous group of MM patients. We analyzed 89 patients with MM treated at two transplant centers in Singapore who received novel agent-based induction chemotherapy, PBSC mobilization with vinorelbine / cyclophosphamide, high-dose melphalan conditioning and autologous stem cell rescue. 61 patients were included in the pegfilgrastim group and 28 in the filgrastim group, with a similar median age and disease characteristics. PBSC harvesting was done at a similar median time of 9...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Until recently, advances in classical Hodgkin lymphoma (HL) treatment primarily consisted of minor modifications of highly effective decades-old chemotherapy and radiation approaches. In early stage disease, excellent outcomes have been reported with fewer cycles of chemotherapy, lower doses and smaller radiation fields, and in some circumstances radiation elimination. In advanced stage disease, maintaining dose intensity of standard chemotherapy regimens has resulted in modest improvements in outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Conclusions Low-dose RT, administered to all sites of original involvement, was associated with improved progression-free survival, even in the setting of a metabolic CR after ABVD. Teaser The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved by PET-CT after chemotherapy. In this series, low-dose (∼20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD. Long-term toxicity was similar between chemotherapy and combined modality therapy.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved according to positron emission tomography-computed tomography imaging after chemotherapy. In this series, low-dose (approximately 20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Long-term toxicity was similar between chemotherapy and combined modality therapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 24 December 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Andrea Tendas, Francesco Marchesi, Ombretta Annibali, Debora Saltarelli, Pasquale Niscola, Alessio Pio Perrotti, William Arcese
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion With the limitations of a retrospective study, these data suggest that consolidative radiotherapy may improve survival in DLBCL patients with a residual mass after chemotherapy, also in advanced disease. Teaser The role of radiotherapy (RT) in Diffuse Large B-cell lymphomas with advanced disease is unclear. In this retrospective study, two cooperating university hospitals in Western Norway had different practices in use of RT, but similar patient characteristics and chemotherapy. RT to a residual mass after chemotherapy, in low-intermediate risk groups with advanced disease, was associated with improved cancer-s...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion The use of consolidative RT after HDC and ASCT for relapsed or refractory DLBCL appears to significantly improve LRC. For patients with masses ≥ 2 cm after ASCT, improved 2-year PFS and OS were seen. Prospective trials are needed to further identify the patients who would derive the most benefit from consolidative RT in the ASCT setting. Micro-Abstract Patients with relapsed or refractory diffuse large B-cell lymphoma undergoing autologous bone marrow transplantation benefited from consolidative involved-field radiotherapy (IFRT). All patients who underwent consolidative IFRT had improved locoregional co...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients. Micro-Abstract We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our res...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We have read with great interest the paper by Trifilio S. and colleagues1, entitled “Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study”. The authors illustrated the result of a retrospective comparative clinical trial of olanzapine-contain ing regimen versus aprepitant or fosaprepitant-containing regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) among patients affected by multiple myeloma undergoing autologous stem cell transplantation (ASCT) with h...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Study | Velcade